Optimizing mavacamten for treatment of obstructive hypertrophic cardiomyopathy
The introduction of mavacamten represents a major shift in the treatment of obstructive hypertrophic cardiomyopathy, but raises dosing and drug-drug interaction challenges.For these reasons, the FDA has mandated that a Risk Evaluation and Mitigation Strategies (REMS) program be undertaken by any institution that prescribes mavacamten (Camzyos, Bristol Myers Squibb). This article will show how a